Kulkarni R D, DaSilva L M, Chabria N L, Chadha D R
Clin Pharmacol Ther. 1977 Jun;21(6):685-90. doi: 10.1002/cpt1977216685.
The relative potency of penbutolol, a new beta adrenergic receptor blocking agent, was compared with propranolol by a four-point assay on healthy male subjects. A dose-response relationship to intravenous doses of propranolol in the microgram range was obtained during a steady state of infusion of epinephrine. Two subjects underwent the entire assay according to the Latin square design and four others each underwent one schedule of design on different days. The potency of penbutolol thus assessed was consistent with reported results. This study emphasizes the importance of intersubject variation and differential receptor sensitivity in individuals. The use of epinephrine as a beta receptor adrenergic agonist for evaluation of selective beta adrenergic receptor blocking activities is discussed.
通过对健康男性受试者进行四点测定,将新型β肾上腺素能受体阻滞剂喷布洛尔的相对效价与普萘洛尔进行了比较。在肾上腺素输注的稳态期间,获得了微克范围内静脉注射普萘洛尔的剂量反应关系。两名受试者按照拉丁方设计完成了整个测定,另外四名受试者分别在不同日期进行了一个设计方案。如此评估的喷布洛尔效价与报道结果一致。本研究强调了个体间差异和个体受体敏感性差异的重要性。讨论了使用肾上腺素作为β受体肾上腺素能激动剂来评估选择性β肾上腺素能受体阻断活性。